A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at . A replay of the webcast will be archived on the ...

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...

Discover the Vanguard Mega Cap Value ETF (MGV) - a value-focused investment option offering low volatility and attractive ...

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

These high-quality investment funds offer a combination of exposure to today's hottest growth trends and diversification ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $43.42, moving -1.83% from the previous trading session.

All of this makes Intuitive a player that could offer you both security and growth this year and beyond. CRISPR ...

CRISPR Therapeutics AG (CRSP) shares rallied 6.5% in the last trading session to close at $44.20. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Here are my three favorite Vanguard ETFs to buy and hold for decades. Warren Buffett doesn't give a seal of approval to ETFs ...

Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics ...